News: The Surgisphere Scandal: What Went... (The Scientist) - Behind the headlines
In the news
Media coverage of health and science topics
The Surgisphere Scandal: What Went Wrong?
The high-profile retractions of two COVID-19 studies stunned the scientific community earlier this year and prompted calls for reviews of how science is conducted, published, and acted upon. The warning signs had been there all along.
Read more at The Scientist
Behind the headlines
Research findings and data from the National Library of Medicine
PubMed articles
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital.
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
Our study confirmed previous observations suggesting that underlying cardiovascular disease is associated with an increased risk of in-hospital death among patients hospi …
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposur …
Related content
Similar articles
Reviews
People also viewed
Also of interest
Additional recent and related news
Major Hydroxychloroquine Trial Shows No Prevention Benefits
A large, double-blind study examined 821 people who had been exposed to the virus. The drug was no better at stopping Covid-19 infection than a placebo.
Malaria Drug Promoted by Trump Did Not Prevent Covid Infections, Study Finds
The first carefully controlled trial of hydroxychloroquine given to people exposed to the coronavirus did not show any benefit.
Column: How a retracted research paper contaminated global coronavirus research
Major retractions on coronavirus research show something is rotten in scientific publishing
Concerns Build Over Surgisphere’s COVID-19 Dataset
NEJM and The Lancet issue expressions of concern as researchers question where the company got its data on thousands of coronavirus patients.
Hydroxychloroquine coronavirus trial to restart
The UK's regulator says testing of the controversial anti-malarial drug can be resumed.